What is GraphWear Technologies?
GraphWear Technologies operates at the intersection of wearable electronics and chronic disease management. The company specializes in the development of innovative, non-invasive glucose monitoring solutions designed to eliminate the discomfort associated with traditional blood-glucose testing. By focusing on user experience and clinical efficiency, GraphWear addresses a critical pain point for the global diabetes population. Their market position is defined by a commitment to high-fidelity data acquisition and seamless integration into the daily lives of patients, effectively bridging the gap between complex medical diagnostics and consumer-grade wearable convenience.
How much funding has GraphWear Technologies raised?
GraphWear Technologies has raised a total of $24.7M across 2 funding rounds:
Series A
$4.2M
Series B
$20.5M
Series A (2018): $4.2M with participation from BioInnovation Capital and Mission Bay Capital
Series B (2021): $20.5M led by VSC Ventures, Builders VC, Mayfield, and BioInnovation Capital
Key Investors in GraphWear Technologies
BioInnovation Capital
BioInnovation Laboratories specializes in in vitro testing, research, development, and consulting services for clients in the pharmaceutical, cosmetic, personal health care, and specialty chemical industries.
Mission Bay Capital
Mission Bay Capital is an early stage life science venture capital firm that focuses on enabling innovative advancements in the life sciences sector.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions that reshape complex systems.
What's next for GraphWear Technologies?
With the successful closure of its latest financing round, GraphWear Technologies is poised to transition from a research-heavy development phase into a broader commercialization strategy. The influx of capital will likely be directed toward clinical validation, regulatory approval processes, and the expansion of manufacturing capabilities to meet anticipated market demand. Furthermore, the strategic involvement of its investor base suggests a focus on scaling enterprise-level partnerships and refining the company's go-to-market strategy. As the firm moves forward, the primary objective will be to solidify its competitive advantage in the glucose monitoring space while maintaining the rigorous standards required for medical-grade health technology.
See full GraphWear Technologies company page
